TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
MetaVia ( (MTVA) ) has shared an announcement.
On August 6, 2025, MetaVia Inc. announced an extension of the 48 mg multiple ascending dose cohort in its Phase 1 clinical trial of DA-1726 for obesity treatment, from 4 to 8 weeks, administering a fifth weekly dose to the first patient. This extension aims to assess early efficacy, patient safety, and tolerability with longer-term exposure, and to explore the non-titrated maximum tolerated dose. Previously reported data showed promising weight loss and safety profiles, suggesting DA-1726 may offer a superior tolerability profile compared to existing GLP-1 therapies. The trial’s top-line data is expected in the fourth quarter of 2025, potentially positioning DA-1726 more strongly against current treatments.
The most recent analyst rating on (MTVA) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on MetaVia stock, see the MTVA Stock Forecast page.
Spark’s Take on MTVA Stock
According to Spark, TipRanks’ AI Analyst, MTVA is a Underperform.
MetaVia’s overall stock score is heavily impacted by its poor financial performance, characterized by persistent losses and no revenue generation. The technical analysis indicates weak market momentum, and negative valuation metrics highlight the stock’s high-risk profile. Although recent positive trial results provide some potential for future growth, significant strategic changes are necessary for the company to achieve financial stability and investor confidence.
To see Spark’s full report on MTVA stock, click here.
More about MetaVia
MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity and DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist, aimed at superior body weight loss compared to selective GLP1R agonists.
Average Trading Volume: 295,661
Technical Sentiment Signal: Sell
Current Market Cap: $11.75M
See more insights into MTVA stock on TipRanks’ Stock Analysis page.